Assessment of feasibility and safety of the addition of ZD6474 (Zactima) [vandetanib] to carboplatin and paclitaxel administered neo-adjuvantly in stage IB, II and T3, N1 non-small cell lung cancer (NSCLC).

Trial Profile

Assessment of feasibility and safety of the addition of ZD6474 (Zactima) [vandetanib] to carboplatin and paclitaxel administered neo-adjuvantly in stage IB, II and T3, N1 non-small cell lung cancer (NSCLC).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2013

At a glance

  • Drugs Vandetanib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 09 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top